Brind.
  1. KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision.
  2. FDA approved KalVista's novel treatment EKTERLY®.

FDA approved KalVista's Ekterly treatment, leading to a royalty agreement with DRI Healthcare.

2 reports, 1 independent Updated Aug 10
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA approved KalVista's Ekterly treatment, leading to a royalty agreement with DRI Healthcare.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Ekterly monetization reached $178M; Lumvoa joins royalty contributors.1 source
  2. DRI Healthcare Trust receives royalties following FDA approval of KalVista's Ekterly.

Keep exploring

Part of

FDA approved KalVista's novel treatment EKTERLY®. All 1 developments

Within KalVista Pharmaceuticals received prior regulatory approvals in the UK and the US, and the EMA adopted a positive opinion for its drug sebetralstat, with the EC expected to make a final decision.

The entities involved

Related events

Coverage

Newest first; wire copies grouped